Payment overview · 2025
General Payments
$694.76
15 reported records · 10 companies
Healthcare provider profile · identity verified
Sarah Cuffee, FNP
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · CHARLESTON, WV · NPI 1134672330
Verified facts
What the public records show
CMS Open Payments records show Sarah Cuffee, FNP received $694.76 in general payments during 2025 across 15 reported records.
AstraZeneca Pharmaceuticals LP accounted for 18.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 12 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jynarque, Kerendia, Lokelma.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 142 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LOKELMA as an associated drug or biological on 6897 records involving 4326 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Lokelma by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Kerendia by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Entresto by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JYNARQUE as an associated drug or biological on 11133 records involving 4164 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Jynarque by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $125.00 | 18.0% | 1 | 2025 |
| Calliditas Therapeutics US Inc. | Unresolved — no canonical attribution shown | $119.38 | 17.2% | 1 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $114.02 | 16.4% | 1 | 2025 |
| NxStage Medical, Inc. | Unresolved — no canonical attribution shown | $94.78 | 13.6% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $67.92 | 9.8% | 4 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $62.93 | 9.1% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $51.45 | 7.4% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $20.92 | 3.0% | 1 | 2025 |
| Alexion Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $20.42 | 2.9% | 1 | 2025 |
| Mallinckrodt Hospital Products Inc. | Unresolved — no canonical attribution shown | $17.94 | 2.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $694.76 | 15 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| LOKELMA Normalized: lokelma |
Drug | AstraZeneca Pharmaceuticals LP | $125.00 | 1 | 2025 |
Source payment records
|
|||||
| TARPEYO Normalized: tarpeyo |
Drug | Calliditas Therapeutics US Inc. | $119.38 | 1 | 2025 |
Source payment records
|
|||||
| XPHOZAH 30 MG Normalized: xphozah 30 mg |
Drug | Ardelyx, Inc. | $114.02 | 1 | 2025 |
Source payment records
|
|||||
| LIBERTY SELECT CYCLER Normalized: liberty select cycler |
Device | NxStage Medical, Inc. | $94.78 | 1 | 2025 |
Source payment records
|
|||||
| NXSTAGE PUREFLOW SOLUTION Normalized: nxstage pureflow solution |
Device | NxStage Medical, Inc. | $94.78 | 1 | 2025 |
Source payment records
|
|||||
| NXSTAGE SYSTEM ONE Normalized: nxstage system one |
Device | NxStage Medical, Inc. | $94.78 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $67.92 | 4 | 2025 |
Source payment records
|
|||||
| JYNARQUE Normalized: jynarque |
Drug | Otsuka America Pharmaceutical, Inc. | $62.93 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $51.45 | 1 | 2025 |
Source payment records
|
|||||
| Fabhalta Normalized: fabhalta |
Drug | Novartis Pharmaceuticals Corporation | $20.92 | 1 | 2025 |
Source payment records
|
|||||
| ULTOMIRIS Normalized: ultomiris |
Biological | Alexion Pharmaceuticals, Inc. | $20.42 | 1 | 2025 |
Source payment records
|
|||||
| TERLIVAZ Normalized: terlivaz |
Drug | Mallinckrodt Hospital Products Inc. | $17.94 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JYNARQUE jynarque |
2025 | Jynarque | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 38 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| LOKELMA lokelma |
2025 | Lokelma | 2024 | 32 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
142 | 44 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | LOKELMA open payments reported associated product |
CMS Open Payments — General Payments 6897 supporting records · 4326 recipient NPIs · example record 1206131624 |
Lokelma · 2024 Exact normalized brand match · 1 Part D row |
32 | 12 |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
38 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
38 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | JYNARQUE open payments reported associated product |
CMS Open Payments — General Payments 11133 supporting records · 4164 recipient NPIs · example record 1227267725 |
Jynarque · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Calcitriol | Calcitriol | 554 | 176 |
| Losartan Potassium | Losartan Potassium | 449 | 140 |
| Chlorthalidone | Chlorthalidone | 281 | 112 |
| Amlodipine Besylate | Amlodipine Besylate | 272 | 108 |
| Torsemide | Torsemide | 251 | 95 |
| Allopurinol | Allopurinol | 215 | 70 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 206 | 75 |
| Spironolactone | Spironolactone | 189 | 71 |
| Carvedilol | Carvedilol | 178 | 64 |
| Jardiance | Empagliflozin | 153 | 54 |
| Farxiga | Dapagliflozin Propanediol | 142 | 44 |
| Hydralazine Hcl | Hydralazine Hcl | 121 | 45 |
| Metoprolol Succinate | Metoprolol Succinate | 103 | 41 |
| Cinacalcet Hcl | Cinacalcet Hcl | 79 | 26 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 76 | 24 |
| Lisinopril | Lisinopril | 64 | 23 |
| Telmisartan | Telmisartan | 61 | 30 |
| Furosemide | Furosemide | 55 | 22 |
| Sevelamer Carbonate | Sevelamer Carbonate | 55 | 26 |
| Atorvastatin Calcium | Atorvastatin Calcium | 51 | 19 |
| Hydrochlorothiazide | Hydrochlorothiazide | 46 | 18 |
| Minoxidil | Minoxidil | 41 | 15 |
| Clonidine Hcl | Clonidine Hcl | 40 | 16 |
| Entresto | Sacubitril/Valsartan | 38 | suppressed |
| Kerendia | Finerenone | 38 | suppressed |
| Lokelma | Sodium Zirconium Cyclosilicate | 32 | 12 |
| Eplerenone | Eplerenone | 31 | suppressed |
| Potassium Chloride | Potassium Chloride | 28 | 12 |
| Mounjaro | Tirzepatide | 27 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 27 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 26 | 12 |
| Paricalcitol | Paricalcitol | 26 | suppressed |
| Metolazone | Metolazone | 24 | 11 |
| Pantoprazole Sodium | Pantoprazole Sodium | 24 | suppressed |
| Prednisone | Prednisone | 23 | suppressed |
| Valsartan | Valsartan | 23 | suppressed |
| Veltassa | Patiromer Calcium Sorbitex | 23 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 22 | suppressed |
| Auryxia | Ferric Citrate | 22 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 21 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 20 | suppressed |
| Finasteride | Finasteride | 17 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 17 | suppressed |
| Clonidine | Clonidine | 16 | suppressed |
| Velphoro | Sucroferric Oxyhydroxide | 16 | suppressed |
| Atenolol | Atenolol | 14 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 14 | suppressed |
| Ozempic | Semaglutide | 14 | suppressed |
| Febuxostat | Febuxostat | 13 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 13 | suppressed |
| Colchicine | Colchicine | 12 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 11 | suppressed |
| Jynarque | Tolvaptan | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $694.76 · 15 records | AstraZeneca Pharmaceuticals LP | Fabhalta, JYNARQUE, Kerendia, LIBERTY SELECT CYCLER, LOKELMA, NXSTAGE PUREFLOW SOLUTION, NXSTAGE SYSTEM ONE, REPATHA, TARPEYO, TERLIVAZ, ULTOMIRIS, XPHOZAH 30 MG | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jynarque play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error